KCNJ2基因的新突变导致长QT间隔综合征7型和学习障碍:一个病例报告
Hua-Yong Zhang1,2, Yong Zhang1,2
1Department of Cardiology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Medicine
|February 19, 2025
概括
长QT综合征7型 (LQT7) 是一种罕见的遗传疾病. 这一案例凸显了管理LQT7心律失常的挑战,表明可植入心脏转换器-除器是其他治疗方法失败时的关键选择.
科学领域:
- 遗传学和分子生物学
- 心脏病学 心脏病学
- 儿科 儿科 儿科
背景情况:
- 长QT综合征7型 (LQT7) 是一种罕见的遗传疾病,影响心脏,神经系统和骨肌肉.
- 它的特点是QT间隔延长,心律失常,周期性,以及明显的身体特征.
- 编码Kir2.1蛋白的KCNJ2基因的突变与LQT7.7有关.
研究的目的:
- 报告一个8岁男孩的LQT7病例,该男孩患有KCNJ2新型基因突变.
- 讨论管理LQT的诊断和治疗方面的挑战7.
- 在LQT7.7中评估危及生命的心脏事件的治疗选择.
主要方法:
- 一个8岁男孩出现心室节律失常和学习障碍的案例报告.
- 基因测序以确定KCNJ2基因中的突变.
- 审查治疗策略,包括β-阻断剂,射频导管切除和植入式心脏转换器-除器.
主要成果:
- 在KCNJ2基因中发现了一种新的误解突变 (c.224 C>A,p.Thr75Lys).
- 该患者经常出现过早的腹腔收缩和双向腹腔心动减速,耐受β-阻塞剂.
- 射频导管切除在治疗心律失常方面没有成功.
- 由于复发性昏迷,建议使用植入式心脏转换器-除器.
结论:
- 管理LQT7需要专注于预防不良心脏事件.
- 在LQT7.7中,β抑制剂可能不会在预防致命性心律失常方面始终有效.
- 射频导管切除可能具有挑战性,可能会失败.
- 植入式心脏转换器-除器是LQT7患者在医疗治疗失败后发生危及生命的心脏事件的可行选择.
相关概念视频
Alternative RNA Splicing
20.9K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
20.9K
Sex-linked Disorders
99.9K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
99.9K
Voltage-gated Ion Channels
7.9K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
7.9K
Karyotyping
56.5K
Overview
56.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
889
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
889


